InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (16 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
16
T+90 hit rate
25%
T+90 mean return
-3.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Congleton Jon, Chief Executive Officer. Insider active across 1 company, notably Mineralys Therapeutics, Inc.. In total, 20 reports have been recorded. Breakdown: 4 buys · 16 sells. Total volume traded: €4.3m. History available since 11 August 2023. The latest transaction was disclosed on 13 April 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations20 total
58,000 sharesCommon StockSEC:0001933414-26-000096:0
17,000 sharesCommon StockSEC:0001933414-26-000096:1
15,730 shares@ US$26.82640.014% mcap11.7% of flowCommon StockSEC:0001933414-26-000075
15,730 shares@ US$26.82640.016% mcap11.7% of flowCommon StockSEC:0001933414-26-000075:0
19,364 shares@ US$25.50060.019% mcap13.9% of flowCommon StockSEC:0001644975-26-000004:0
19,364 shares@ US$25.50060.017% mcap13.9% of flowCommon StockSEC:0001644975-26-000004
9,119 shares@ US$32.20830.011% mcap8.2% of flowCommon StockSEC:0001644975-26-000002:0
9,119 shares@ US$32.20838.2% of flowCommon StockSEC:0001644975-26-000002
13,548 shares@ US$42.629516.2% of flowCommon StockSEC:0001933414-25-000129
13,548 shares@ US$42.62950.022% mcap16.2% of flowCommon StockSEC:0001933414-25-000129:0
15,319 shares@ US$12.19423.9% of flowCommon StockSEC:0001933414-25-000044:0
18,333 shares@ US$9.05923.8% of flowCommon StockSEC:0001933414-25-000003:0
15,271 shares@ US$13.5184.4% of flowCommon StockSEC:0001933414-24-000045:0
15,746 shares@ US$13.34154.5% of flowCommon StockSEC:0001933414-24-000033:0
17,766 shares@ US$12.25444.7% of flowCommon StockSEC:0001933414-24-000032:0
16,607 shares@ US$12.76654.6% of flowCommon StockSEC:0001933414-24-000029:0
4,250 shares@ US$5.96610.5% of flowCommon StockSEC:0001933414-23-000093:0
Ideal exit: 18 Aug 2024 (T+270)
2,250 shares@ US$12.080.6% of flowCommon StockSEC:0001933414-23-000067:0
Ideal exit: 2 Jun 2024 (T+270)
2,250 shares@ US$12.100.6% of flowCommon StockSEC:0001933414-23-000065:0
Ideal exit: 13 May 2024 (T+270)
2,000 shares@ US$12.890.5% of flowCommon StockSEC:0001933414-23-000061:0
Ideal exit: 7 May 2024 (T+270)
20 of 20 declarations
About Congleton Jon
Congleton Jon is the Chief Executive Officer of Mineralys Therapeutics, Inc. He leads the company in the biotechnology sector, focusing on developing innovative treatments. His role is essential in guiding Mineralys towards innovation and growth in the healthcare field.
